Tumor necrosis factor inhibitors in pediatric asthma

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 3, Issue 2, 2009, Pages 143-148

  Gjurow, Daniela ^a   Grzelewski, Tomasz ^a   Sobocińska, Agnieszka ^a   Stelmach, Iwona ^a  

^a N Copernicus Hospital   (Poland)

Author keywords

Anti TNF ; Asthma; Benefit risk ratio; Bronchial hyperresponsiveness; Children

Indexed keywords

BCG VACCINE; CORTICOSTEROID; ENTARECEPT; ETANERCEPT; GLUCOCORTICOID; GOMALIMUMAB; INFLIXIMAB; INTERFERON; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ADALIMUMAB; ANTIASTHMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; OMALIZUMAB; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ALLERGIC ASTHMA; ALLERGIC REACTION; ARTHRALGIA; ASTHMA; BIOLOGICAL ACTIVITY; BRONCHUS HYPERREACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; HEART FAILURE; HEART PALPITATION; HEMATOLOGIC DISEASE; HEMIPLEGIA; HEPATITIS B; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSTIMULATION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MALIGNANT NEOPLASTIC DISEASE; MOUTH DISEASE; NEUTROPENIA; NONHUMAN; PATENT; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VACCINATION; CHILD; DRUG ANTAGONISM; IMMUNOLOGY;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68949167604     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221309788489797     Document Type: Review

References (44)

1. Kim J, Remick DJ. Tumor necrosis factor inhibitors for the treatment of asthma. Curr Allergy Asthma Rep 2007; 7: 151-156.
2. Greenlee RT, Chyou PH, Kieke A, et al. Prevalence of asthma in a general population cohort of farm children: comparision of estimates based on parental report and medical record review. J Acromed 2008; 13: 225-231.
3. Glushkova AV, Grjibovski AM. Prevalence and correlates of asthma among children in central St. Petersburg, Russia: crosssectional study. Croat Med J 2008; 49: 741-750.
4. Brighting C, Berry M, Amrani Y. Targeting TNF-α: A novel therapeutic approach for asthma. J Allergy Clin Immunol 2008; 121: 5-10.
5. Wagelie-Streffen Al, Kavanaugh AF, Wasserman SI. Biologic therapies for the treatment of asthma. Clin Chest Med 2006; 27: 133-147.
6. Howarth PH, Babu KS, Arshad HS, et al. Tumor necrosis factor-α (TNF-α)as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-1018.
7. Antoniu SA. Entarecept for refractory asthma therapy. Expert Opin Investig Drugs 2006; 15: 1279-1281.
8. Antoniu SA. Targeting tumour necrosis factor- α in corticosteroid-depedent asthma. Expert Opin Ther Targets 2006; 10: 471-473.
9. Tarantini F, Baiardini I, Passalacqua G, et al. Asthma treatment: Magic bullets which seek their own targets. Allergy 2007; 62: 605-610.
10. Holgate ST. Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine 2004; 28: 152-157.
11. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005; 52: 1227-1236.
12. Breedveld FC, Kavanaugh AF, Cohen SB, et al. Early treatment of rheumatoid arthritis (RA) with adalimumab (HUMIRA®) plus methotrexate vs adalimumab alone or methotrexate alone: The PREMIER study. In program book supplement to the 2004 ACR/ARHP annual scientific meeting; 2004; Antonio, TX. Presentation L5. Hoboken NJ: John Wiley and Sons 2004; pp. 16-21.
13. Davis JCJ, Van Der HD, Braun J, et al.. Recombinant human tumor necrosis factor receptor (entarecept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-3236.
14. Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9: 1245-1250.
15. Jerzyńska J, Stelmach W, Majak P, et al. Effect of specific immunotherapy on serum levels of tumor necrosis factor alpha in asthmatic children. Allergy Asthma Proc 2008; 29: 274-279.
16. Mukhopadhyay S, Hoidal JR, Mukherjee T. Role of TNF-α in pulmonary pathophisiology. Respir Res 2006; 7: 125.
17. Eck MJ, Sprang SR. The structure of tumor necrosis factor- α at 2.6 Å resolution. Implications for receptor binding. J Biol Chem 1989; 246: 17595-17605.
18. Russo C, Polosa R. TNF-α as a promising therapeutic target in chronic asthma: A lesson from rheumatoid arthritis. Clin Sci 2005; 109: 135-142.
19. Lin J, Ziring D, Desai S, et al. TNFα blockade in human diseases: An overview of efficacy and safety. Clin Immunol 2008; 126: 13-30.
20. Ohkawara Y, Yamauchi K, Tanno Y, et al. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-α in sensitized lung tissue after IgE receptor triggering. Am J Respir Cell Mol Biol 1992; 7: 385-392.
21. Berry, M.A., Hargadon, B., Shelley, M., Parker, D., Shaw, D.E., Green, R.H., Bradding, P., Brightling, C.E., Wardlaw, A.J., Pavord, I.D.: NCT00276029 (2006).
22. Busse PJ, Zhang TF, Srivastava K, et al. Chronic exposure to TNFalpha increases airway mucus gene expression in vivo. J Allergy Clin Immunol 2005; 116: 1256-1263.
23. Levine SJ, Larivee P, Logun C, et al. Tumor necrosis factor-α induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells. Am J Respir Cell Moll Biol 1995; 12: 196-204.
24. Lora JM, Zhang DM, Liao SM, et al. Tumor necrosis factor-alpha triggers mucus production in airway epithelium through an IkappaB kinase beta-dependent mechanism. J Biol Chem 2005; 280: 36510-36517.
25. Garcia-Martinez, L., Jensen, A. E. C., Olson, K., Dutzar, B., Ojala, E., Latham, J.: WO08144753A2 (2008).
26. Leo, O., Galli, M., Van Gool, F.: WO08138943A2 (2008).
27. Bathon JM, Martin RW, Fleischmann RM, et al. A comparision of entarecept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-1593.
28. Brandt J, Khariouzov A, Listing J, et al. Six-months results of a double-blind, placebo controlled trial of entarecept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-1675.
29. Glickman RM. Inflammatory Bowel Disease: Ulcerative Colitis and Crohn's Disease. In: Faluce AS, Branwald E, Eds. Harrison's Principles of Internal Medicine, 14th ed. New York: McGraw-Hill 1998; pp. 1633-1645.
30. Mease PJ, Kivitz AJ, Burch FX, et al. Entarecept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-2272.
31. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358(9278): 295-296.
32. Adams A, Lehman TJ. Update on patogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Curr Opin Rheumatol 2005; 17: 612-616.
33. Hyams JS, Crandall SW, Kugathasan R, et al. A randomized, multicenter, open-label study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate-to-severe Crohn's disease. J Pediatr Gastroenterol 2007; 23: 359-399.
34. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-α therapies. J Cutan Med Surg 2005; 9: 296-302.
35. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am J Respir Crit Care Med 2006; 174: 753-762.
36. Rouhani FN, Meitin CA, Kaler M, et al. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med 2005; 99: 1175-1182.
37. Morjaria JB, Chauchan AJ, Bobu KS, et al. Assessment of a soluble TNFalpha receptor fusion protein (entarecept) as a novel therapeutic agent for severe refractory asthma. Proc Am Thorc Soc 2006; 3: A16.
38. Bogartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
39. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 926-934.
40. Furst D, Wallis R, Broder M, et al. Tumor necrosis factor antagonists: Different kinetics and/or mechanisms, of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006; 36: 159-167.
41. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-379.
42. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Reum 2006; 54: 2757-2764.
43. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-1426.
44. Wang, B., Jin, H., Jin, J., Kang, Y.: WO08148306A1 (2008).